No abstract

No abstract

Background: Bibliometric analyses are a tool employed by researchers and funding agencies to establish the most important areas of research in a particular field, and to determine which foci need increased research attention. Such analyses have been published in a variety of clinical specialties; however, a detailed literature search showed that no such study has been done for “myeloid neoplasms.” In order to bridge this gap, we conducted a citation analysis of the 100 most influential articles on myeloid neoplasms. Methods: Two independent researchers extracted relevant articles from the Scopus database. These articles were then ranked in descending order of citations and a list of the top 100 original articles was made. A further, more detailed list was created containing significant discriminating characteristics. Results: The top cited articles were published over a period of 47 years, with most of them being published in the 5-year interval of 2001–2005. The citations ranged from 636 to 4,039. The articles originated from 28 different countries. Most of the articles were published in high-impact journals. Conclusion: Our analysis sheds light on the quality of work and driving trends, listing the most cited and impactful guideline articles within this field and aiding clinicians.

Dear Madam, Pembrolizumab side effects have affected 60% of the patients. Some f side effects include thyroid dysfunction, hepatitis and pneumonitis and Auto- immune diabetes which can prove to be dangerous in pandemic times [1]. If not kept in check, endocrine dysfunction can belife- threatening. Recent studies showed that Pembrolizumab, when administered to patients previously on Ipilimumab can aggravate autoimmune diabetes. [2] Another case reported that a 70 years old patient was found suffering from liver and lung malignancies and later diagnosed with induced Diabetic ketoacidosis and isolated adrenocorticotrophic hormone deficiency after being administered with both Ipilimumab and Pembrolizumab as part of treating the malignancies [3]. Another study which was conducted recently showed that within 3 months of administering PD?1/PD?L1 inhibitor, the patients developed Type 1 Diabetes rapidly along with a higher incidence of ketoacidosis. [4] In light of the above evidence, health care professionals should be aware of this rare, life-threatening side effect of Pembrolizumab. Strict monitoring of patients’ blood glucose levels to whom Pembrolizumab is being administered should be done along with the history of any other PD-1/PD-L1 inhibitor that was administered before. Keywords: Pembrolizumab, Immunotherapy, Endocrine dysfunction, Type I diabetes.

New milestones have been reached in oncology with the advent of a noninvasive, photodynamic therapy which aims to eradicate cancer cells rapidly. A chemical compound, Nitrobenzaldehyde, injected into the tumor, activates by ultraviolet (UV) light and disrupts the cancer cells' internal and external dynamics. This technique could be of enormous therapeutic value in destroying numerous cancer lines including breast, prostate, pancreatic cancers, etc., without causing unwanted systemic side effects.